Analyst Profile

Followed by 214 followers
.
Eric Joseph

Eric Joseph

J.P. Morgan
Wall Street Analyst
#1,546 out of 8,160 Wall Street Analysts
#3,224 out of 24,427 experts

Success Rate

55%
56 out of 101 transactions made a profit

Average Return

+8.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Eric Joseph's trades since 2019 and holding each position for 1 Year would result in 55.45% of your transactions generating a profit, with an average return of 8.8% per rating.

Stock Rating Distribution

182Ratings
48.90% Buy
41.21% Hold
9.89% Sell
Distribution of Eric Joseph's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Akero Therapeutics
(AKRO)
Rating:Buy
Date:Jul 15, 2022 - Today
Return:+321.10%
The most profitable rating made by Eric Joseph

Eric Joseph's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
MLNTQ
Melinta Therapeutics
Jun 14, 2019
Sell
Downgraded
1Ratings
100%
+93.40%
Precigen
Feb 07, 2020
Hold
Reiterated
1Ratings
0.00%
MNTA
Momenta Pharma
Aug 19, 2020
Hold
Downgraded
3Ratings
100%
+74.20%
Urogen Pharma
Sep 21, 2020
Hold
Reiterated
$26.00
(209.89% Upside)
3Ratings
0.00%
ObsEva SA
Nov 09, 2020
Sell
Downgraded
3Ratings
0%
-51.45%
UROV
Urovant Sciences
Nov 16, 2020
Hold
Downgraded
3Ratings
50%
+1.75%
XLRN
Acceleron Pharma
Jan 29, 2021
Buy
Reiterated
4Ratings
100%
+64.05%
Autolus Therapeutics
Jan 29, 2021
Hold
Downgraded
$9.00
(202.01% Upside)
2Ratings
0%
-44.30%
FPRX
Five Prime Therapeutics
Mar 04, 2021
Hold
Reiterated
3Ratings
0%
-369.90%
Freeline Therapeutics Holdings
Aug 17, 2021
Hold
Downgraded
$8.00
(1190.32% Upside)
2Ratings
0%
-78.80%
List of latest recommendations made by Eric Joseph. Click to expand and see Eric Joseph's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >